• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Clearant Announces Fourth Tissue Bank Launch of Orthopedic Tissue Implants Treated With the CLEARANT PROCESS(R)

Posted on: Monday, 8 August 2005, 09:01 CDT

Clearant, Inc (OTCBB: CLRI) and DCI Donor Services (DCI), an affiliation of organ and tissue recovery organizations across the U.S., announced today the complete conversion of the DCI soft tissue allograft product line to the CLEARANT PROCESS(R) sterilization method. DCI is the fourth tissue bank to launch commercially available soft tissue allografts treated with the CLEARANT PROCESS(R) for orthopedic implants. DCI is also the second tissue bank to have completely deployed the CLEARANT PROCESS(R) for all its soft tissue allografts.

"Due to the increase in surgeon demand for sterile - safer - allografts, we are very excited to have implants treated with the CLEARANT PROCESS(R) available to meet this need," said Kelli Orr, Executive Director, DCI Donor Services.

Dr. Ty Endean (orthopedic surgeon for the US Rugby team) implanted the first allograft from DCI treated with the CLEARANT PROCESS(R). Both Dr. Endean and Dr. Derek Jones (team orthopedic surgeon for the New Orleans Saints and New Orleans Hornets) have been involved in a Clearant clinical outcome data collection over the last year and have had zero allograft implant failures.

"We've had successful outcomes with all the allografts treated with the CLEARANT PROCESS(R) - no infections or allograft failures," reported Dr. Jones. "I am excited about DCI offering tissue treated with the CLEARANT PROCESS(R). Recent studies demonstrate the need to eliminate the potential for infections from allografts that are not sterilized, and we believe these DCI allografts treated with the CLREARANT PROCESS(R) resolve this issue."

About DCI Donor Services

The mission of DCI Donor Services is to support families in member communities who have sustained the loss of a loved one by providing an opportunity for the donation of anatomical gifts and by facilitating the recovery and transplantation of these gifts to individuals in need. DCI currently recovers and processes tissue from approximately 1,000 donors annually, resulting in the processing of approximately 25,000 transplant allografts. Additionally, they provide tissue to researchers within their recovery service area to promote the advancement of scientific investigation and medical therapy.

About Clearant, Inc

Clearant, Inc., a biotechnology company headquartered in Los Angeles, California, is a leader in pathogen inactivation for biological products. Clearant(R) has developed the patent-protected CLEARANT PROCESS(R), designed to substantially reduce all types of pathogens in biological products while maintaining a high degree of the underlying protein. Various sterilization methods on the market today only kill specific types of pathogens, such as bacteria or lipid-enveloped viruses, for specific products. The CLEARANT PROCESS(R) can substantially reduce all types of pathogens for products across many market segments including plasma proteins, tissue implants, recombinant products and blood products, and can be applied at various stages of product processing/manufacturing, including in the final container. Clearant is actively involved in licensing the CLEARANT PROCESS(R) in applications to a number of biological products including tissue allografts, recombinant proteins and plasma products among others.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the biotechnology industry, and additional risks discussed in the company's filings with the SEC. For more information about Clearant, Inc., please see www.clearant.com.

Source: Business Wire

More News in this Category